{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T06:10:42Z","timestamp":1673676642767},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The high incidence of Gleason score upgrading (GSU) made urologists underestimate the disease, leading to the inaccurate therapeutic decision. The study aimed to explore relevant laboratory examination evidence associated with GSU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with prostate carcinoma undergoing radical prostatectomy in our center between January 2015 and December 2019 were included in this retrospective study. Patients were divided into GSU and NGSU groups according to the occurrence of GSU. Medical records were reviewed and analyzed between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 130 patients were enrolled, including 52 patients diagnosed with GS\u2009=\u20096 (20 NGSU and 32 GSU) and 78 patients with GS\u2009=\u20097 (36 NGSU and 42 GSU). No significant differences in demographic characteristics were found between groups. An increased neutrophil count (OR\u2009=\u20091.326, 95% CI\u2009=\u20091.005\u20131.748) and a decreased percentage of lymphocytes (OR\u2009=\u20090.951, 95% CI\u2009=\u20090.904\u20131) were associated with GSU in the GS\u2009=\u20096 group, whereas a high HDL level (OR\u2009=\u20097.735, 95% CI\u2009=\u20090.998\u201359.957) was associated with GSU in GS\u2009=\u20097 group. Preoperative high neutrophile count and low lymphocyte percentage were correlated with GSU in patients with low-grade prostate cancer. In contrast, high HDL level was associated with GSU in patients with high-grade prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These laboratory examination data could provide urologists with information before making a therapeutic protocol.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-022-01155-9","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T06:02:58Z","timestamp":1673330578000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A high high-density lipoprotein level is associated with Gleason score upgrade in Chinese patients diagnosed with high-grade prostate carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Jingcheng","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"1155_CR1","first-page":"249","volume":"55","author":"G Pourmand","year":"2017","unstructured":"Pourmand G, Gooran S, Hossieni SR, Guitynavard F, Safavi M, Sharifi A, et al. Correlation of preoperative and radical prostatectomy gleason score: examining the predictors of upgrade and downgrade results. Acta Med Iran. 2017;55:249\u201353.","journal-title":"Acta Med Iran"},{"key":"1155_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5152\/tud.2018.57946","volume":"45","author":"T Turan","year":"2019","unstructured":"Turan T, G\u00fc\u00e7l\u00fcer B, Efilo\u011flu \u00d6, \u015eendo\u011fan F, At\u0131\u015f RG, \u00c7a\u015fkurlu T, et al. The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system. Turk J Urol. 2019;45:36\u201341.","journal-title":"Turk J Urol"},{"key":"1155_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.eururo.2008.03.049","volume":"54","author":"MS Cohen","year":"2008","unstructured":"Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol. 2008;54:371\u201381.","journal-title":"Eur Urol"},{"key":"1155_CR4","first-page":"1","volume":"6","author":"F Qi","year":"2019","unstructured":"Qi F, Zhu K, Cheng Y, Hua L, Cheng G. How to pick out the \u201cUnreal\u201d Gleason 3 + 3 patients: a nomogram for more precise active surveillance protocol in low-risk prostate cancer in a Chinese population. J Invest Surg. 2019;6:1\u20138.","journal-title":"J Invest Surg"},{"key":"1155_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.humpath.2018.05.011","volume":"79","author":"S Prathibha","year":"2018","unstructured":"Prathibha S, Goyal K, Zynger D. Initial diagnosis of insignificant cancer, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, and negative have the same rate of upgrade to a Gleason score of 7 or higher on repeat prostate biopsy. Hum Pathol. 2018;79:116\u201321.","journal-title":"Hum Pathol"},{"key":"1155_CR6","doi-asserted-by":"crossref","unstructured":"Su ZT, Patel HD, Epstein JI, Pavlovich CP, Allaf ME. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy\u00a0to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. Cancer 2020.","DOI":"10.1002\/cncr.32709"},{"issue":"4","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4111\/icu.2020.61.4.405","volume":"61","author":"DM Pham","year":"2020","unstructured":"Pham DM, Kim JK, Lee S, Hong SK, Byun SS, Lee SE. Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance? Investig Clin Urol. 2020;61(4):405\u201310.","journal-title":"Investig Clin Urol"},{"issue":"1","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12894-020-00711-5","volume":"20","author":"V Novak","year":"2020","unstructured":"Novak V, Vesely S, Luksanov\u00e1 H, Prusa R, Capoun O, Fiala V, et al. Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer. BMC Urol. 2020;20(1):144.","journal-title":"BMC Urol"},{"key":"1155_CR9","doi-asserted-by":"publisher","first-page":"9483935","DOI":"10.1155\/2019\/9483935","volume":"2019","author":"FM Wang","year":"2019","unstructured":"Wang FM, Zhang Y. High lipoprotein(a) Level is independently associated with adverse clinicopathological features in patients with prostate cancer. Dis Markers. 2019;2019:9483935.","journal-title":"Dis Markers"},{"issue":"2","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41391-017-0030-9","volume":"21","author":"J Jamnagerwalla","year":"2018","unstructured":"Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018;21(2):252\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1155_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41391-018-0087-0","volume":"22","author":"TJ Murtola","year":"2019","unstructured":"Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(1):66\u201376.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11\u201312","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"E383","DOI":"10.5489\/cuaj.3550","volume":"10","author":"MI Gokce","year":"2016","unstructured":"Gokce MI, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J. 2016;10(11\u201312):E383\u20137.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41391-017-0015-8","volume":"21","author":"M \u00d6zsoy","year":"2018","unstructured":"\u00d6zsoy M, Moschini M, Fajkovic H, Soria F, Seitz C, Klatte T, et al. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. Prostate Cancer Prostatic Dis. 2018;21(1):100\u20135.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/13685538.2020.1772227","volume":"23","author":"TM Shelton","year":"2020","unstructured":"Shelton TM, Greenberg JW, Silberstein JL, Krane LS. Hematologic parameters are not predictors of upgrading or treatment in a racially diverse prospective study of men with prostate cancer on active surveillance. Aging Male. 2020;23(5):1400\u20138.","journal-title":"Aging Male"},{"issue":"1","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93\u2013103.","journal-title":"Br J Cancer"},{"issue":"24","key":"1155_CR16","doi-asserted-by":"publisher","first-page":"8252","DOI":"10.1074\/jbc.RA120.013694","volume":"295","author":"CA Traughber","year":"2020","unstructured":"Traughber CA, Opoku E, Brubaker G, Major J, Lu H, Lorkowski SW, et al. Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice. J Biol Chem. 2020;295(24):8252\u201361.","journal-title":"J Biol Chem"},{"key":"1155_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/pcan.2009.54","volume":"13","author":"D Colleselli","year":"2010","unstructured":"Colleselli D, Pelzer AE, Steiner E, Ongarello S, Schaefer G, Bartsch G, et al. Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis. 2010;13:182\u20135.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4111\/icu.2017.58.2.90","volume":"58","author":"GD Santok","year":"2017","unstructured":"Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, et al. Prostate-specific antigen 10\u201320 ng\/mL: a predictor of degree of upgrading to 8 among patients with biopsy Gleason score 6. Investig Clin Urol. 2017;58(2):90\u20137.","journal-title":"Investig Clin Urol"},{"issue":"3","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41391-019-0132-7","volume":"22","author":"C De Nunzio","year":"2019","unstructured":"De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R, Collura D, et al. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer Prostatic Dis. 2019;22(3):491.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1155_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.urology.2017.07.071","volume":"111","author":"A Brassetti","year":"2018","unstructured":"Brassetti A, Lombardo R, Emiliozzi P, Cardi A, Antonio V, Antonio I, et al. Prostate-specific antigen density is a good predictor of upstaging and upgrading, according to the new grading system: the keys we are seeking may be already in our pocket. Urology. 2018;111:129\u201335.","journal-title":"Urology"},{"issue":"6","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ejso.2017.12.003","volume":"44","author":"C De Nunzio","year":"2018","unstructured":"De Nunzio C, Pastore AL, Lombardo R, Simone G, Leonardo C, Mastroianni R, et al. The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. Eur J Surg Oncol. 2018;44(6):835\u20139.","journal-title":"Eur J Surg Oncol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-01155-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:14:08Z","timestamp":1673622848000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-01155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-01155-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Capital Medical University Beijing Friendship Hospital (Approval number: 2020-P2-034-01). All procedures followed applicable guidelines and regulations. The informed written consent was also obtained from the patients in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}